Dr. Reddy's announces Q1 2015 results

HYDERABAD, India — Dr. Reddy's Labs announced financial results for the quarter ended June 30, which includes consolidated revenues of Rs.35.2 billion, representing year-on-year growth of 24%.



Revenues from the global generics segment came in at Rs.29.0 billion, a year-on-year growth of 32%. Revenues from the pharmaceutical services and active ingredients segment, however, showed a year-on-year decline of 6% at Rs.5.5 billion.



During the quarter, Dr. Reddy's launched 25 new generic products and filed 27 new product applications and 20 DMFs globally.